Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Randomised, Double-blind, Placebo-controlled Incomplete Crossover Trial With 4-week Treatment Periods to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution (Doses of 1.25 mircog, 2.5 microg and 5 microg) Delivered Via Respimat Inhaler Once Daily in the Evening in Children 6 to 11 Yrs Old With Moderate Persistent Asthma.

Next Previous
Search
Trial Profile

A Phase II Randomised, Double-blind, Placebo-controlled Incomplete Crossover Trial With 4-week Treatment Periods to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution (Doses of 1.25 mircog, 2.5 microg and 5 microg) Delivered Via Respimat Inhaler Once Daily in the Evening in Children 6 to 11 Yrs Old With Moderate Persistent Asthma.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tiotropium bromide (Primary)
  • Indications Asthma
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors Boehringer Ingelheim Pharmaceuticals

Most Recent Events

  • 01 Apr 2018 Results of pooled data from vitro compared with nine clinical trial assessing PK exposure to tiotropium in preschool children with persistent asthmatic symptoms (using test VHC), were published in the Respiratory Medicine.
  • 18 May 2016 Results of five trials (n=1397) presented at the 112th International Conference of the American Thoracic Society
  • 20 Oct 2012 Planned number of patients changed from 101 to 104.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top